Johnson & JohnsonJNJ
JNJ
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
149% more first-time investments, than exits
New positions opened: 430 | Existing positions closed: 173
25% more call options, than puts
Call options by funds: $2.64B | Put options by funds: $2.11B
5% more funds holding
Funds holding: 3,829 [Q3] → 4,004 (+175) [Q4]
1.62% more ownership
Funds ownership: 70.16% [Q3] → 71.78% (+1.62%) [Q4]
6% less capital invested
Capital invested by funds: $274B [Q3] → $257B (-$16.8B) [Q4]
23% less funds holding in top 10
Funds holding in top 10: 189 [Q3] → 145 (-44) [Q4]
30% less repeat investments, than reductions
Existing positions increased: 1,327 | Existing positions reduced: 1,908
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$152
0%
upside
Avg. target
$165
9%
upside
High target
$181
19%
upside
9 analyst ratings
4 positive
44%
5 neutral
56%
0 negative
0%
B of A Securities Tim Anderson 43% 1-year accuracy 6 / 14 met price target | 5%upside $159 | Neutral Maintained | 10 Apr 2025 |
Morgan Stanley Terence Flynn 33% 1-year accuracy 7 / 21 met price target | 8%upside $164 | Equal-Weight Maintained | 9 Apr 2025 |
Goldman Sachs Asad Haider 50% 1-year accuracy 1 / 2 met price target | 13%upside $172 | Buy Upgraded | 9 Apr 2025 |
RBC Capital Shagun Singh 32% 1-year accuracy 22 / 69 met price target | 19%upside $181 | Outperform Reiterated | 3 Apr 2025 |
Barclays Matt Miksic 37% 1-year accuracy 15 / 41 met price target | 9%upside $166 | Equal-Weight Maintained | 28 Jan 2025 |
Financial journalist opinion
Based on 100 articles about JNJ published over the past 30 days
Neutral
CNBC
13 hours ago
Jim Cramer's week ahead: Earnings from Goldman Sachs, Johnson & Johnson and Netflix
CNBC's Jim Cramer on Friday told investors which market-moving events to follow next week. He pinpointed earnings reports from major banks like Goldman Sachs, as well as Johnson & Johnson and Netflix,
Positive
Seeking Alpha
19 hours ago
Johnson & Johnson: Fairly Valued, But Recession-Resilient
Johnson & Johnson offers stability and limited downside risk, making it a solid investment in volatile markets, despite not being a high-growth stock. The company's fiscal 2024 results showed moderate growth in sales and earnings, with notable performance in the oncology and cardiovascular segments. Analysts expect low-to-mid single-digit growth for Johnson & Johnson, with a focus on operational efficiency and share buybacks to boost the bottom line.
Positive
Zacks Investment Research
19 hours ago
Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. We do not expect any improvement in MedTech sales.
Negative
CNBC
21 hours ago
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Positive
The Motley Fool
1 day ago
2 Top Dividend Stocks to Buy Right Now
Microsoft (MSFT -2.33%) and Johnson & Johnson (JNJ -1.64%) are leading companies in their respective industries. They both have impressive track records and have made their long-term shareholders significantly richer.
Neutral
Zacks Investment Research
1 day ago
Seeking Clues to Johnson & Johnson (JNJ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Neutral
PRNewsWire
2 days ago
Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill
ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 SPRING HOUSE, Pa. , April 10, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from a subgroup analysis of ICONIC-LEADa, the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis (PsO) to assess efficacy and safety of a systemic therapy in adolescents and adults simultaneously.
Positive
The Motley Fool
2 days ago
Stock Market Sell-Off Shopping Spree: 3 Top Dividend Stocks I Just Bought to Boost My Passive Income
Stock market sell-offs like the one we're currently experiencing are challenging periods for investors. However, with every challenge comes an opportunity to improve.
Positive
CNBC
2 days ago
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties on goods from China to 125% and citing a "lack of respect.
Positive
The Motley Fool
2 days ago
The Dow Crashed 4,260 Points in 3 Days: Here Are 3 Dow Stocks That Make for No-Brainer Buys Right Now
Long before the S&P 500 became Wall Street's benchmark index, the iconic Dow Jones Industrial Average (^DJI 7.87%) was viewed as the best barometer of the stock market's health. Since its inception in May 1896, the Dow has evolved from a 12-stock, industrial-focused index to one that now houses 30 time-tested, multinational companies.
Charts implemented using Lightweight Charts™